EMA Working On New Guidance For Infectious And Respiratory Diseases, Biosimilars
Executive Summary
Companies can expect to see a number of finalized and draft EU guidelines published throughout 2018 and into 2019, according to newly published work plans for the European Medicines Agency’s Infectious Disease Working Party, Biosimilar Medicinal Products Working Party and the Respiratory Drafting Group.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.